REMODULIN - REMODULIN - CT 6327 - English version

Has

Description

Introduction REMODULIN 1 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 161-5) REMODULIN 2.5 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 162-1) REMODULIN 5 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 163-8) REMODULIN 10 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 164-4) Posted on Jan 05 2011 Active substance (DCI) treprostinil sodium Pneumologie - Mise au point Progrès thérapeutique : – important pour FLOLAN ; – modéré pour TRACLEER ; – mineur pour ADCIRCA, REMODULIN, REVATIO, VENTAVIS et VOLIBRIS Les médicaments de l’hypertension artérielle pulmonaire (HTAP) n'apportent qu'un bénéfice symptomatique, et celui-ci est modeste. FLOLAN (époprosténol) est le seul ayant montré une augmentation de la survie. Son rapport efficacité/effets indésirables est donc important ; il est modéré pour les autres médicaments. Il s’agit de médicaments de première intention, excepté REMODULIN et VENTAVIS, qui sont utilisés en deuxième intention. N.B. – THELIN a été retiré du marché en raison de son risque d'atteinte hépatique sévère. Pour en savoir plus télécharger la synthèse ou l'avis complet ci-dessous ATC Code B01AC21 Laboratory / Manufacturer BIOPROJET PHARMA REMODULIN 1 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 161-5) REMODULIN 2.5 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 162-1) REMODULIN 5 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 163-8) REMODULIN 10 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 164-4) Posted on Jan 05 2011

Sujets

• Maladie génétique
• RARE

Informations

• Publié par: haute-autorite-sante-maladies-appareil-respiratoire
• Publié le: 05 janvier 2011
• Nombre de lectures: 136
• Licence : En savoir +
  Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
• Langue: English

Extrait

 

    The legally binding text is the original French version   TRANSPARENCY COMMITTEE

  OPINION   5 January 2011     REMODULIN 1 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 161-5) REMODULIN 2.5 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 162-1) REMODULIN 5 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 163-8) REMODULIN 10 mg/ml, solution for infusion (subcutaneous route) 20-ml glass vial (CIP code: 368 164-4)     Applicant: BIOPROJET PHARMA   treprostinil sodium ATC code: B01AC21   List I Medicine for hospital prescription only, restricted to specialists and/or departments specialising in pneumology or cardiology.   Date of Marketing Authorisation (by mutual recognition): 28 February 2005     Reason for examination: Reassessment of actual benefit and improvement in actual benefit under article R-163-21 of the Social Security Code.     Indications:   “Treatment of primitive pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms of the disease in patients in NYHA (New York Heart Association) functional class III.”   Dosage: see SPC   The Transparency Committee has reassessed all treatments for PAH. Distinctions have been drawn between the various proprietary drugs (see complete report attached). The Transparency Committee’s conclusions regarding REMODULIN were as follows:          

 

1/2

Actual benefit PAH is a rare pulmonary condition that affects life expectancy. It is characterised by gradual blocking of the small pulmonary arteries, leading to a gradual increase in pulmonary arterial pressure and right cardiac insufficiency. PAH is defined by an increase in mean pulmonary arterial pressure (mPAP) measured by cardiac catheterisation which is equal to or greater than 25 mmHg at rest, with no increase in pulmonary capillary pressure. Asthenia, dyspnoea, chest pain, and loss of consciousness are the most frequent clinical signs. Median survival under symptomatic treatment is around 2.5 years for patients with functional class III PAH and is 4.8 years.   All treatments for PAH are symptomatic. The efficacy/adverse effects ratio is moderate. In practice, prostacyclins are used as second-line treatment. No public health benefit is expected.   The actual benefit is moderate.   Improvement in actual benefit (IAB) The Transparency Committee is of the opinion that the REMODULIN range of proprietary drugs provides a minor improvement in actual benefit (IAB IV) in the treatment of idiopathic pulmonary arterial hypertension for patients in functional class III.                                 Medical, Economic and Public Health Assessment Division

 

2/2